Ubiquinol improves symptoms in children with autism

Anna Gvozdjáková, Jarmila Kucharská, Daniela Ostatníková, Katarína Babinská, Dalibor Nakládal, Fred L Crane, Anna Gvozdjáková, Jarmila Kucharská, Daniela Ostatníková, Katarína Babinská, Dalibor Nakládal, Fred L Crane

Abstract

Background: Autism is a spectrum of neurodevelopmental disorders with manifestation within 3 years after birth. Manifestations of autism include behavior problems (hyperactivity, toys destruction, self-harm, and aggression) and sleep and eating disorders. Etiology of autism is poorly understood. Oxidative stress and antioxidants can participate in pathobiochemical mechanisms of autism.

Methods: Twenty-four children, aged 3-6 years, with autism according to the DSM IV criteria and using CARS were included in the study. Concentrations of CoQ10-TOTAL, γ- and α-tocopherol, β-carotene, and lipid peroxidation were determined in plasma before and after three months of supportive therapy with ubiquinol at a daily dose 2 × 50 mg. Data on behavior of the children were collected from parents at the same time.

Results: Ubiquinol supportive therapy improved symptoms in children with autism, as communication with parents (in 12%), verbal communication (in 21%), playing games of children (in 42%), sleeping (in 34%), and food rejection (in 17%), with CoQ10-TOTAL plasma level above 2.5 μmol/L.

Conclusions: Beneficial effect of ubiquinol in children with autism has been demonstrated for the first time. We assume that plasma concentration of CoQ10-TOTAL and lipid peroxidation could be used as relevant biomarkers of ubiquinol supportive therapy.

Figures

Figure 1
Figure 1
Proposed novel Coenzyme Q binding site in Voltage Dependent Anion Channel of outer mitochondrial membrane. CoQ—Coenzyme Q; VDAC—Voltage Dependent Anion Channel; ATP—adenosine triphosphate; ADP—adenosine diphosphate; Pi—inorganic phosphate; I, II, III, IV, and V—respiratory chain complexes; H+—proton; e−—electron; Q-cycle—Coenzyme Q cycle; cyt c—cytochrome c; NADH—reduced nicotinadenindinucleotid; NAD+—nicotinadenindinucleotid; FADH2—reduced flavinadenindinucleotid; FAD—flavinadenindinucleotid; O2 ∙−—superoxide radical; H2O2—hydrogen peroxide; OH∙—hydroxyl radical; H2O—water; O2—oxygen.

References

    1. Rossignol DA, Frye RE. Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis. Molecular Psychiatry. 2012;17(3):290–314.
    1. Kumar B, Prakash A, Sewal RK, Medhi B, Modi M. Drug therapy in autism: a present and future perspective. Pharmacological Reports. 2012;64:1291–1304.
    1. Giulivi C, Zhang Y-F, Omanska-Klusek A, et al. Mitochondrial dysfunction in autism. Journal of the American Medical Association. 2010;304(21):2389–2396.
    1. Ghanizadeh A, Berk M, Farrashbandi H, Shoushtari AA, Villagonzalo KA. Targeting the mitochondrial electron transport chain in autism, a systematic review and synthesis of a novel therapeutic approach. Mitochondrion. 2012;13(5):515–519.
    1. Napoli E, Wong S, Giulivi C. Evidence of reactive oxygen species-mediated damage to mitochondrial DNA in children with typical autism. Molecular Autism. 2013;4, article 2
    1. Chauhan A, Chauhan V. Oxidative stress in autism. Pathophysiology. 2006;13(3):171–181.
    1. Heberling CA, Dhurjati PS, Sasser M. Hypothesis for a systems connectivity model of autism spectrum disorder pathogenesis: link to gut bacteria, oxidative stress, and intestinal permeability. Medical Hypotheses. 2013;80(3):264–270.
    1. Zoroglu SS, Armutcu F, Ozen S, et al. Increased oxidative stress and altered activities of erythrocyte free radical scavenging enzymes in autism. European Archives of Psychiatry and Clinical Neuroscience. 2004;254(3):143–147.
    1. Al-Gadani Y, El-Ansary A, Attas O, Al-Ayadhi L. Metabolic biomarkers related to oxidative stress and antioxidant status in Saudi autistic children. Clinical Biochemistry. 2009;42(10-11):1032–1040.
    1. Parellada M, Moreno C, Mac-Dowell K, et al. Plasma antioxidant capacity is reduced in Asperger syndrome. Journal of Psychiatric Research. 2012;46(3):394–401.
    1. Frustaci A, Neri M, Cesario A, et al. Oxidative stress-related biomarkers in autism: systematic review and meta-analyses. Free Radical Biology and Medicine. 2012;52(10):2128–2141.
    1. Yorbik O, Sayal A, Akay C, Akbiyik DI, Sohmen T. Investigation of antioxidant enzymes in children with autistic disorder. Prostaglandins Leukotrienes and Essential Fatty Acids. 2002;67(5):341–343.
    1. Gvozdjakova A, Mravec B, Kucharska J, et al. Increased ubiquinone concentration after intracerebroventricularly-administered ubiquinol to selected rat brain regions. General Physiology and Biophysics. 2012;31(4):469–472.
    1. Schopler E, Reichler RJ, DeVellis RF, Daly K. Toward objective classification of childhood autism: Childhood Autism Rating Scale (CARS) Journal of Autism and Developmental Disorders. 1980;10(1):91–103.
    1. Janero DR, Burghardt B. Thiobarbituric acid-reactive malondialdehyde formation during superoxide-dependent, iron-catalyzed lipid peroxidation: influence of peroxidation conditions. Lipids. 1989;24(2):125–131.
    1. Lang JK, Gohil K, Packer L. Simultaneous determination of tocopherols, ubiquinols, and ubiquinones in blood, plasma, tissue homogenates, and subcellular fractions. Analytical Biochemistry. 1986;157(1):106–116.
    1. Kucharska J, Gvozdjakova A, Mizera S, et al. Participation of coenzyme Q10 in the rejection development of the transplanted heart: a clinical study. Physiological Research. 1998;47(6):399–204.
    1. Mosca F, Fattorini D, Bompadre S, Littarru GP. Assay of coenzyme Q10 in plasma by a single dilution step. Analytical Biochemistry. 2002;305(1):49–54.
    1. Meguid NA, Dardir AA, Abdel-Raouf ER, Hashish A. Evaluation of oxidative stress in autism: defective antioxidant enzymes and increased lipid peroxidation. Biological Trace Element Research. 2011;143(1):58–65.
    1. Krajcovicova-Kudlackova M, Valachovicova M, Mislanova C, Hudecova Z, Sustrova M, Ostatnikova D. Plasma concentrations of selected antioxidants in autistic children and adolescents. Bratislavské Lekárske Listy. 2009;110(4):247–250.
    1. Chauhan A, Gu F, Essa MM, et al. Brain region-specific deficit in mitochondrial electron transport chain complexes in children with autism. Journal of Neurochemistry. 2011;117(2):209–220.
    1. Filipek PA, Juranek J, Nguyen MT, Cummings C, Gargus JJ. Relative carnitine deficiency in autism. Journal of Autism and Developmental Disorders. 2004;34(6):615–623.
    1. Oliveira G, Diogo L, Grazina M, et al. Mitochondrial dysfunction in autism spectrum disorders: a population-based study. Developmental Medicine and Child Neurology. 2005;47(3):185–189.
    1. Rossignol DA, Bradstreet JJ. Evidence of mitochondrial dysfunction in autism and implications for treatment. American Journal of Biochemistry and Biotechnology. 2008;4(2):208–217.
    1. Srinivasan SM, Bhat AN. A review of “music and movement” therapies for children with autism: embodied interventions for multisystem development. Frontiers in Integrative Neuroscience. 2013;7, article 22
    1. Rossignol DA. Novel and emerging treatments for autism spectrum disorders: a systematic review. Annals of Clinical Psychiatry. 2009;21(4):213–236.
    1. Gvozdjakova A, Kucharska J, Babinska K, et al. Effect of ubiquinol on oxidative stress, antioxidants and psychological manifestations in children with autism. Proceedings of the 7th Conference of the International Coenzyme Q10 Association; November 2012; Seville, Spain.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit